Compounds > plakortide f
Page last updated: 2024-11-12

plakortide f

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

plakortide F: from Plakortis halichondrioides; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10450815
CHEMBL ID482405
SCHEMBL ID7220898
MeSH IDM0268751

Synonyms (4)

Synonym
plakortide f
methyl 2-[(3s,4s,6s)-4,6-diethyl-6-[(e)-4-ethyloct-5-enyl]dioxan-3-yl]acetate
CHEMBL482405
SCHEMBL7220898
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID358598Antiparasitic activity against Toxoplasma gondii RH infected in mouse L929 cells assessed as [3H]uracil incorporation at 1 uM after 72 hrs by scintillation counting2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358605Antibacterial activity against methicillin-resistant Staphylococcus aureus2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358600Antifungal activity against Aspergillus fumigatus2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358595Antiviral activity against Hepatitis B virus cell culture assay2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358591Cytotoxicity against human A549 cells by alamar blue assay2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358604Antibacterial activity against Staphylococcus aureus2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358603Antibacterial activity against Pseudomonas aeruginosa2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358599Antifungal activity against Candida albicans2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358592Cytotoxicity against human SK-MEL-28 cells by alamar blue assay2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358588Antimalarial activity as parasitaemia against Plasmodium berghei ANKA infected Swiss albino mice (Mus musculus) at 100 uM/kg intraperitoneal dose after 3 days2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID400680Induction of Ca2+ uptake in sarcoplasmic reticular-vesicle isolated from dog cardiac ventricle at 10 to 100 uM by fluorimetric method1996Journal of natural products, Mar, Volume: 59, Issue:3
Plakortides, novel cyclic peroxides from the sponge Plakortis halichondrioides: activators of cardiac SR-CA(2+)-pumping ATPase.
AID358587Antimalarial activity against Plasmodium berghei ANKA infected Swiss albino mice (Mus musculus) intraperitoneal dose over 3 days2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358593Antimalarial activity as increased survival against Plasmodium berghei ANKA infected Swiss albino mice (Mus musculus) at 100 uM/kg intraperitoneal dose2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID468188Displacement of [3H]NPY from neuropeptide Y1 receptor in human SK-N-MC cells at 10 ug/ml after 60 mins by scintillation counting2009Journal of natural products, Dec, Volume: 72, Issue:12
5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID358586Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358596Antitubercular activity against Mycobacterium tuberculosis at 6.25 ug/mL2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358590Cytotoxicity against human HT-29 cells by alamar blue assay2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358602Antibacterial activity against Mycobacterium intracellular2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358601Antifungal activity against Cryptococcus neoformans2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358585Antimalarial activity against Plasmodium falciparum D62001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358589Cytotoxicity against mouse P388 cells by alamar blue assay2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID358594Antiviral activity against Human immunodeficiency virus2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID468187Displacement of [3H]NPY from neuropeptide Y1 receptor in human SK-N-MC cells at 100 ug/ml after 60 mins by scintillation counting2009Journal of natural products, Dec, Volume: 72, Issue:12
5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID468186Displacement of [3H]BQ-123 from human ETA receptor in human SK-N-MC cells at 10 ug/ml after 60 mins by scintillation counting2009Journal of natural products, Dec, Volume: 72, Issue:12
5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID468185Displacement of [3H]BQ-123 from human ETA receptor in human SK-N-MC cells at 100 ug/ml after 60 mins by scintillation counting2009Journal of natural products, Dec, Volume: 72, Issue:12
5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		210aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		210azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
lamivudine
[no description available]		210monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
atovaquone
Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.		210hydroxy-1,2-naphthoquinone
sceptrin
sceptrin: structure given in first source; isolated from marine sponges of the genus Agelas; RN from CHEMLINE		2.0510pyrroles;
secondary carboxamide
tamoxifen
[no description available]		210stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
bibp 3226
BIBP 3226: a selective non-peptide neuropeptide Y Y1 receptor antagonist; structure given in first source; BIBP-3435 is the S-enantiomer		2.0510
chlorhexidine
Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.		2.0510biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
endothelins
[no description available]		2.0510
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		210cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		0210
Hepatitis B Virus Infection
[description not available]		0210
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		0210
Cancer of Lung
[description not available]		0210
Neoplasm Metastasis, Unknown Primary
[description not available]		0210
Colonic Neoplasms
Tumors or cancer of the COLON.		0210
Hepatitis B
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.		0210
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		0210
Lung Neoplasms
Tumors or cancer of the LUNG.		0210